1. Home
  2. ATHR vs FDMT Comparison

ATHR vs FDMT Comparison

Compare ATHR & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATHR
  • FDMT
  • Stock Information
  • Founded
  • ATHR 2003
  • FDMT 2013
  • Country
  • ATHR United States
  • FDMT United States
  • Employees
  • ATHR N/A
  • FDMT N/A
  • Industry
  • ATHR
  • FDMT Biotechnology: Pharmaceutical Preparations
  • Sector
  • ATHR
  • FDMT Health Care
  • Exchange
  • ATHR NYSE
  • FDMT Nasdaq
  • Market Cap
  • ATHR 200.4M
  • FDMT 207.1M
  • IPO Year
  • ATHR 2025
  • FDMT 2020
  • Fundamental
  • Price
  • ATHR $11.19
  • FDMT $4.13
  • Analyst Decision
  • ATHR
  • FDMT Buy
  • Analyst Count
  • ATHR 0
  • FDMT 10
  • Target Price
  • ATHR N/A
  • FDMT $32.33
  • AVG Volume (30 Days)
  • ATHR 53.0K
  • FDMT 449.2K
  • Earning Date
  • ATHR 05-16-2025
  • FDMT 08-07-2025
  • Dividend Yield
  • ATHR N/A
  • FDMT N/A
  • EPS Growth
  • ATHR N/A
  • FDMT N/A
  • EPS
  • ATHR N/A
  • FDMT N/A
  • Revenue
  • ATHR $1,406,012.00
  • FDMT $23,000.00
  • Revenue This Year
  • ATHR N/A
  • FDMT $13,048.65
  • Revenue Next Year
  • ATHR N/A
  • FDMT N/A
  • P/E Ratio
  • ATHR N/A
  • FDMT N/A
  • Revenue Growth
  • ATHR N/A
  • FDMT N/A
  • 52 Week Low
  • ATHR $4.63
  • FDMT $2.24
  • 52 Week High
  • ATHR $19.69
  • FDMT $28.93
  • Technical
  • Relative Strength Index (RSI)
  • ATHR N/A
  • FDMT 54.45
  • Support Level
  • ATHR N/A
  • FDMT $4.21
  • Resistance Level
  • ATHR N/A
  • FDMT $4.62
  • Average True Range (ATR)
  • ATHR 0.00
  • FDMT 0.30
  • MACD
  • ATHR 0.00
  • FDMT -0.02
  • Stochastic Oscillator
  • ATHR 0.00
  • FDMT 37.42

About ATHR AETHER HOLDINGS INC

Aether Holdings Inc is an emerging financial technology platform company that offers proprietary research analytics, data and tools for both institutional and retail equity traders through flagship platform, SentimenTrader.com. Its platform currently provides coverage of U.S. equity and option securities, evaluating the equities and options markets and conducting assessments through analysts and technology daily.

About FDMT 4D Molecular Therapeutics Inc.

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Share on Social Networks: